Nektar Therapeutics NKTR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $55.23M-43.9% | $98.43M+9.2% | $90.12M-2.1% | $92.06M-9.7% | ||
| $55.23M-18.5% | $67.74M+20.2% | $56.35M-20.0% | $70.42M-8.6% | ||
| 100%+31.2pp | 68.8%+6.3pp | 62.5%-14.0pp | 76.5%+0.9pp | ||
| $117.33M-3.0% | $120.91M+5.9% | $114.16M-47.7% | $218.32M-45.5% | ||
| $68.67M-10.5% | $76.75M-0.9% | $77.42M-16.2% | $92.33M-24.8% | ||
| $195.33M-4.1% | $203.63M-42.4% | $353.81M-24.4% | $468.22M-14.6% | ||
| -$140.1M— | —— | -$263.68M+29.9% | -$376.17M+15.7% | ||
| -253.7%— | —— | -292.6%+116pp | -408.6%+29.1pp | ||
| -$15.39M-9.9% | -$14M-11.4% | -$12.57M— | —— | ||
| -$155.49M-23.2% | -$126.2M+54.3% | -$276.26M+24.3% | -$364.98M+30.3% | ||
| —— | -$239K-19.5% | -$200K-106% | $3.22M+473% | ||
| -$164.08M-30.0% | -$126.22M+54.3% | -$276.06M+25.0% | -$368.2M+29.7% | ||
| -297.1%-169pp | -128.2%+178pp | -306.3%+93.7pp | -400%+114pp | ||
| -$10.03-15.6% | -$8.68-495% | -$1.46+25.9% | -$1.97+99.8% | ||
| -$139.08M-20.8% | -$115.16M+55.0% | -$255.87M+29.5% | -$363.14M+15.9% | ||
| -251.8%-135pp | -117%+167pp | -283.9%+111pp | -394.5%+29.4pp | ||
| -$140.1M-17.2% | -$119.55M+54.7% | -$263.68M+29.9% | -$376.17M+15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -242.0%, with a -284.2% net margin.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.